Onyx Pharmaceuticals acquired California-based Proteolix and its lead candidate, carfilzomib, in a deal valued at up to US$851 M. Carfilzomib is a proteasome inhibitor in clinical trials for treatment of multiple myeloma, non-Hodgkin’s lymphoma and solid tumour cancers.